Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Context Therapeutics Inc.

NASDAQ: CNTX · Life Sciences · 2 alerts · CIK 1842952

Share price
$0.1659Close, Nov 16
Market cap
$15.2M
Shares outstanding
91.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Context Therapeutics Inc. filings on SEC EDGAR ↗

4:24 PM ET 8-K
Financial Results

Context Therapeutics Financial Results

Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.

Term
Q3 2026

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”

Martin Lehr, Chief Executive Officer
4:12 PM ET 10-Q
Financial Results

Context Therapeutics Q3 2026 Results: Net Loss of $7.62M, Loss Narrows

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on the development of CTIM-76 and CT-202, while winding down its CT-95 Phase 1 clinical trial. As of November 6, 2026, the company had 91,879,177 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.

Key figure
Net loss $7.62M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.